Panobinostat, a histone deacetylase inhibitor, is being tested in humans against cutaneous T cell lymphoma, prostate cancer, myelodysplastic syndromes, breast cancer, chronic myelogenous leukemia, and other types of malignant disease. Panobinostat inhibited histone deacetylase and induced acetylation of histone H3 and alpha-tubulin protein in human umbilical vein endothelial cells (HUVEC), which resulted in induction of G(2)-M cell cycle arrest and inhibition of HUVEC proliferation and viability. Panobinostat at noncytotoxic concentrations inhibited endothelial tube formation, Matrigel invasion, AKT activity, extracellular signal-regulated kinase 1/2 phosphorylation and chemokine receptor CXCR4 expression. It aslo reduced angiogenesis and PC-3 tumor growth in mice.
Solubility:
Soluble in DMSO at 200mg/ml; soluble in ethanol at 5mg/ml with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50uM buffers, serum, or other additives may increase or decrease the aqueous solubility.
Melting Point:
156-168C
Elemental Anaylsis:
Calculated:
C=70.09%
H=6.77%
N=11.68%
Storage and Stability:
May be stored at RT for short-term only. Long-term storage is recommended at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Quick Search
Products 
